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Abstract: The secretome of cancer cells is a valuable source of biomarkers that can ultimately reach the serum
or other body fluids. Cancer biomarkers can facilitate early diagnosis and monitoring of the disease, contribute
to our understanding of tumor biology, and support the development of more efficient therapies. Recently,
high-throughput proteomic analysis of the conditioned media of cancer cell lines has shown potential to identify
novel biomarkers in cancer. We used two-dimensional gel electrophoresis coupled to liquid chromatography
tandem mass spectrometry to identify the secretome of the large cell lung cancer cell lines QU-DB and Mehr-80,
which were established from a Canadian and a Persian patient, respectively. A total of 130 distinct protein
species were identified. Most of them were previously found in serum or other body fluids, the membrane
compartment or conditioned media of other cancer cell lines. Some of the proteins that we identified, e.g. IL-6,
triosephosphate isomerase, PGP9.5, a-enolase, Dickkopf-1, and peroxiredoxin-1 have been already known as
putative serum markers for lung cancer, whereas others might be candidate markers for further validation in
lung cancer body fluids such as IL-25, stathmin, vimentin, peptidyl-prolyl cis-trans isomerase A, transgelin-2,
and chloride intracellular channel protein 4. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 3, 368–374)
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Introduction
Cancer cell communications are substantially influ-
enced by their secretome, a collection of molecules
that are shed (membrane and membrane-bound pro-
teins) or secreted either through classical (proteins
with a signal peptide) or nonclassical (intracellular
proteins) pathways. The identification of cancer cell
secretome has uncovered mechanisms related to an-
giogenesis, invasion and metastasis, and can contrib-
ute to the development of new strategies for the effi-
cient control of cancer. Moreover, secreted or shed
proteins can reach body fluids including serum, an
ideal sample source for early diagnosis and monitor-
ing of cancer [1–3].
The mortality rate is still high in lung cancer. Novel
lung cancer serum biomarkers are needed, because
those identified to date, such as cancer embryonic
antigen and squamous cell carcinoma (SCC) antigen,
lack sufficient specificity and sensitivity to serve as an
efficient biomarker [1].
Although serum contains tumor markers, mask-
ing low abundant proteins by high abundant albumin
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and globulins makes serum high-throughput analysis
unreliable. To overcome this drawback, proteomic
identification of conditioned media of cancer cell lines
has recently attracted much attention [1–3]. Gener-
ally, the identified proteins were already known to be
involved in cancer development and progression, and
subsequent studies validated the presence of several
of them in sera from cancer patients. For example,
more than 1,000 proteins in conditioned media from
four lung cancer cell lines of different histological
backgrounds (small-cell lung cancer H1688, adeno-
carcinoma line H23, SCC cell line H520, and large
cell lung carcinoma (LCC) line H460) have been iden-
tified. Using different search tools, the most promis-
ing candidates for validation in sera were then select-
ed, and increased levels of some of them were con-
firmed in sera of lung cancer patients [1].
Based on the size and appearance of the malig-
nant cells, lung cancers are divided into small cell lung
carcinoma (SCLC) and non-small cell lung carcino-
ma (NSCLC); the latter type accounts for more than
80% of all lung tumors [1]. Among the three major
subtypes of NSCLC (adenocarcinoma, SCC and
LCC), LCC (9% of all lung cancers) has the poorest
prognosis. This poorly differentiated lung cancer con-
sists of large cells with abundant cytoplasm and large
nuclei. The neuroendocrine variant of LCC has the
worst prognosis [4, 5].
The secretome of two established LCC cell lines
QU-DB and Mehr-80 have not been investigated to date.
Cell line QU-DB was established from a primary lung
tumor of a 70 year-old man with LCC in Canada, and
Mehr-80, a neuroendocrine variant of LCC, was estab-
lished from the pleural effusion of a 40 year-old woman
in Iran [4, 5]. To find novel lung cancer biomarkers, the
present study analyzed the conditioned media of the two
LCC cell lines using two-dimensional gel electrophore-
sis (2DE) coupled to mass spectrometry (MS).
Material and methods
Cell culture and preparation of conditioned media. The study
was approved by the Ethics Committee of Shiraz University
of Medical Sciences. The QU-DB and Mehr-80 LCC cells
were purchased from the Pasteur Institute of Iran. They were
cultured in 150 cm2 flasks (Nunc, Roskilde, Denmark) at 37°C
(5% CO2 and 95% air) in RPMI-1640 (Biosera, Ringmer,
UK) plus 10% FBS (Biosera), and 100 U/mL penicillin
with100 μg/mL streptomycin (Biosera) until they reached 70–
–80% confluence. The media were then discarded, and the
cells washed three times with PBS and incubated in 30 mL
RPMI with 8 mM L-glutamine (Sigma–Aldrich, Steinheim,
Germany) for another 24 h. The media were collected and
centrifuged at 4°C (200 × g, 10 min) to remove debris, fol-
lowed by sterile filtration by cell culture filters (JET BIO-
FIL, Guangzhou, China) with a 0.2 μm pore size. The col-
lected media were frozen at –80°C until use. The cell viability
was checked by the trypan blue dye exclusion method.
Each cell line was grown in six batches with 30 mL se-
rum-free medium. Two 30-mL batches were combined for
each cell line, then a protease inhibitor cocktail (Roche,
Penzberg, Germany) was added to a 1 × final concentra-
tion, and the mixture was dialyzed overnight at 4°C using
a 3.5-kDa molecular mass cutoff membrane in 10 L of 1 mM
ammonium bicarbonate buffer (Sigma) with four solution
changes. The dialyzed media were frozen and lyophilized
to dryness. Three lyophilized samples per cell line were
obtained from the three combinations of two 30-mL por-
tions of media. To prepare the media to be used as a nega-
tive control, the above procedure was repeated with the
culture media without cells.
After lyophilization, the samples were resuspended in lysis
buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2% immobilized
pH gradient (IPG) buffer (pH 3–10) (GE Healthcare, Uppsa-
la, Sweden)), aliquoted and stored at –80°C. The protein con-
centration was determined by the Bradford protein method
and bovine serum albumin (Sigma, Germany) as standard.
Two-dimensional gel electrophoresis. The first dimension-
al isoelectric focusing (IEF) was done with the Protean IEF
cell system (Bio-Rad, Philadelphia, PA, USA). Approxi-
mately 250 μg of the protein sample was applied per IPG
strip (pH 3–10 nonlinear, 18 cm) by active rehydration
(50 V, 20 C) for 14 h in rehydration buffer (2 M thiourea
(Merck, Darmstadt, Germany), 8 M urea, 2% w/v CHAPS,
0.3% wt/vol DTT, 2% vol/vol IPG 3-10 buffer and bromophe-
nol blue) followed by IEF for a total of 90,000 Vh.
After IEF, each strip was equilibrated in 10 mL equili-
bration buffer (50 mM Tris, pH 8.8, 6 M urea, 30% wt/vol
glycerol, 2% wt/vol SDS) containing 65 mM DTT (fist step)
and 135 mM idoacetamide (second step) at room tempera-
ture for 15 min. Then the equilibrated strips were sealed on
the top of two-dimensional 12% polyacrylamide gels with
a Protean II xi 2-D Cell (Bio-Rad) at 15 mA/gel for 10 min
and then 25 mA/gel until the bromophenol blue dye front
reached the bottom of the gels. The gels were visualized
with an analytical silver staining technique, scanned with
a GS-800 calibrated densitometer (Bio-Rad) and analyzed
with Prodigy SameSpots version 1.0 software (Nonlinear
Dynamics, Newcastle, UK) according to the manufactur-
er’s instructions. The reagents were purchased from GE
Healthcare, Uppsala, Sweden, except where stated.
Liquid chromatography-mass spectrometry (LC-MS/MS).
The spots of interest were picked up from gels that were
stained with a preparative MS-compatible silver staining
method. For in-gel digestion of proteins, the spots were
destained, reduced, alkylated, and finally digested with se-
quencing grade modified trypsin (Promega, Madison, WI,
USA). The resulting peptides were extracted, and lyo-
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philized using a vacuum drier. Lyophilized samples were
resuspended in 0.1% formic acid (FA) prior to LC-MS/MS
analysis. An Agilent 1100 LC/MSD trap XCT was used for
HPLC and MS/MS. Solutions used were water/0.1% FA and
ACN/0.1% FA. A trap column (G 1375-87320, 105 mm,
25 μm; Agilent, Germany) was connected to a standard col-
umn (Zorbax 300 SB-C18, 3.5 μm, 0.3 × 75 mm). Peptides
(12 μl) were loaded on a trapping column and desalted. The
elution program was 2–60% B for 55 min, 80% B for 8 min
and re-equilibration of 2% B for 10 min, for a total run of
78 min. The MS was operated in standard scan mode for
MS analysis and in ultra scan mode for MS/MS analysis.
The MS/MS data was analyzed with the Spectrum Mill da-
tabase search engine (Agilent, Palo Alto, CA, USA) against
the Swiss-Prot database (released May, 2010).
Results
We used 2DE and LC-MS/MS to identify proteins in
the conditioned media of the LCC cell lines QU-DB
and Mehr-80. To reduce the likelihood of intracellu-
lar protein contamination, the secretome were col-
lected from 24-h serum-free culture media because
the trypan blue exclusion test showed a low rate of
cell death (less than 2%) over 24 h. Three gels were
run for each cell line, and the similarity of gels was
found to be more than 80%. Collectively, 395 repro-
ducible, distinct, intense spots were excised from all
gels. Of these 395 spots, 141 were found in the condi-
tioned media of both cell lines, of which 116 were
identified by MS. For 96 of the 116 spots, MS was
done in just one cell line, but for 20 of them (spots
2–4, 24, 25, 29, 34, and 35 in Table 1, and 64, 65, 68,
86, 100, 102, 112, 115, 116, 132–134 in Supplementa-
ry File 1), MS was done in both cell lines to establish
that spots with the same position in gels from each
cell line represented the same polypeptide. Seventy-
two of the 395 spots were hardly-visible/invisible on
Mehr-80 gels, and 41 were hardly-visible/invisible on
QU-DB gels. Of these unique spots, 39 were identi-
fied by MS analysis.
The identified proteins were related to 130 pro-
tein species that were essentially involved in protein
folding, the cytoskeleton, signal transduction, cell
growth, metabolism and redox regulation (Table 1 and
Supplementary File 1). By searching in Swiss-Prot and
published articles, the majority of proteins were found
to have been previously detected in body fluids, the
conditioned media of cancer cell lines, and/or relat-
ed to the cell membrane in humans [1–35]. Each of
these proteins was usually present in more than one
of these locations. Of them, 38 were already found in
serum or other body fluids in pathological conditions
(Table 1). Their descriptions and positions on gels are
displayed in Table 1 and Figure 1. Other proteins,
which were essentially related to cell membrane/mem-
brane-bound or common to those in prior publica-
tions on cancer cell secretome [3], are listed in Table 2
(Supplementary File 1).
Discussion
To identify candidate extracellular biomarkers for lung
cancer, the conditioned media of QU-DB and Mehr-80
LCC cell lines were subjected to 2DE and MS analy-
sis. Most of the 130 identified proteins were already
found in body fluids/in vivo tumor microenvironment,
conditioned media of other cancer cell lines, or relat-
ed to the cell membrane in humans [1–35], the loca-
tions supporting the possibility that a protein might be
secreted or shed. It is known that some intracellular
proteins, particularly those with increased concentra-
tions in body fluids, may be secreted by a variety of
mechanisms such as exocytosis of secretory vesicles or
exomes [1, 3, 11]. Despite optimized cell confluence
and incubation times during media preparation, the
presence of some of the intracellular proteins in con-
ditioned media probably resulted from cell death.
Fifteen of the identified proteins in conditioned
media of QU-DB and Mehr-80, e.g. IL-6, triosephos-
phate isomerase, PGP9.5, high mobility group pro-
tein B1, Dickkopf-1, and peroxiredoxin-1 were already
known to be putative serum markers for lung cancer
[1, 2, 6–16]. Twenty three of the identified proteins
have been previously found in human body fluids or
the in vivo tumor microenvironment in pathological
conditions other than lung cancer (Table 1) [17–35],
indicating that they might be products of cellular se-
cretion. Among them, those known to be overex-
pressed in lung cancer such as 78-kDa glucose-regu-
lated protein [14], epidermal fatty acid-binding pro-
tein [36], transgelin-2 [37], hsp27 [38], stress-induced
phosphoprotein 1 [38], vimentin [39], and transketo-
lase [40] may be more appropriate candidate biom-
arkers for further validation in body fluids from lung
cancer patients.
In the conditioned media of the QU-DB and
Mehr-80, in addition to IL-6, we also found two mem-
bers of the cytokine family with classical signal pep-
tides for secretion: ILE1 and IL-25 [34, 35]. The
former is associated with epithelial-to-mesenchymal
transition and metastasis in breast cancer [34], where-
as the latter is a mediator of type-2 immune respons-
es. Moreover, IL-25 was reported to have a patho-
genic role in allergic lung diseases, and was up-regu-
lated in nasal lavage fluid [35]. It has been shown that
epithelial cells, myeloid cells, eosinophils, basophils
and mast cells produce IL-25 [35], and its presence in
conditioned media of several cancer cell lines includ-
ing lung has recently been reported [3].
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Table 1. Descriptions of the 38 proteins identified in conditioned media of QU-DB and Mehr-80 lung cancer cell lines that have
been previously reported in human body fluids in pathological conditions. Spots numbers are the same as those in Figure 1
Spot Protein name Predicted Accession noa Score/numbers Locationsb Function
no. pI/MW of matched
peptides
1, 2 Peroxiredoxin-1 8.27/22.1 Q06830 55/5 Serum [8] Redox regulation
3, 4 Glutathione S-transferase P 5.43/23.3 P09211 79/5 Serum [13] Redox regulation
5 High mobility group protein B1 5.61/24.8 P09429 129/10 Serum [6] Immune response
6, 7 Triosephosphate isomerase (TPI) 6.45/26.6 P60174 377/23 Serum [12] Metabolism
8, 9 a-enolase 7.01/47.1 P06733 160/11 Serum [7] Metabolism
10 Peroxiredoxin-6 6/25 P30041 279.65/19 Serum [12] Redox regulation
11 Superoxide dismutase (Mn), 8.34/24.7 P04179 72/5 Serum [2] Redox regulation
mitochondrial
12, 13 L-lactate dehydrogenase B chain 5.71/36.6 P07195 249/17 Serum [1] Metabolism
14, 15 Dickkopf-related protein 1 8.8/28.6 O94907 79/5 Serum [9] Signal transduction
16 Ubiquitincarboxyl-terminal 5.33/24.8 P09936 85/7 Serum [11] Thiol protease
hydrolase isozyme L1(PGP9.5)
17 Interkeukin-6 (IL-6) 6.18/23.7 P05231 99/6 Serum [10] Cytokine,
inflammatory
response
18, 19 Plasminogen activator inhibitor 1 6.67/45 P05121 289/19 Serum [2] Protease inhibitor/
/metabolism
20 Isocitrate dehydrogenase 6.53/46.6 O75874 98/8 Serum [16] TCA cycle
[NADP] cytoplasmic
21 Phosphoglycerate kinase 1 8.3/44.6 P00558 267/18 Serum [14] Metabolism
22 Insulin-like growth 7.48/35.1 P18065 109/7 Serum [15] Signal transduction
factor-binding protein 2
23 Protein FAM3C (ILE1) 8.25/24.6 Q92520 46/3 In vivo tumor Cytokine, signal
microenvironment transduction
[34]
24 Chloride intracellular 5.09/26.9 O00299 79/6 Serum [24] Ion transport
channel protein 1 (CLIC1)
25, 26 Protein DJ-1 6.33/19.8 Q99497 113/8 Serum [23] Protein folding
27 L-lactate dehydrogenase A chain 8.44/36.6 P00338 206/15 Serum [22] Metabolism
28–31 Glyceraldehyde-3-phosphate 8.57/37.4 P04406 35/2 Serum [18] Metabolism
dehydrogenase
32, 33 Protein disulfide-isomerase A3 5.99/56.7 P30101 72/6 Serum [20] Protein folding
(ERp57)
34 Stress-induced phosphoprotein 1 6.4/62.6 P31948 250/18 Serum [21] Protein folding
(STIP1)
35 Proteasome activator complex 5.6/29 P61289 83/5 Serum [19] Protein
subunit 3 (PSME3) degradation
36 78 kDa glucose-regulated protein 5.07/72.3 P11021 657/42 Serum [20] Metabolism
37 Heat shock 27 kDa protein (hsp27) 5.98/22.7 P04792 45/4 Serum [20] Protein folding
38 Vimentin 5.06/53.6 P08670 52/3 Serum [17] Cell motility,
cytoskeleton
39 Peroxiredoxin-4 5.86/30 Q13162 72/5 Serum [25] Redox regulation
40 Epidermal fatty acid-binding 6.6/15.1 Q01469 20/1 Serum [26] Transport
protein (E-FABP)
41 Adenylyl cyclase-associated 8.27/57 Q01518 32/2 Urine [27] Cell mobility,
protein-1 (CAP1) cytoskeleton
42 UPF0556 protein C19orf10 (IL-25) 6.2/18.7 Q969H8 76/5 Nasal lavage [35] Signal
transduction
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43 Inorganic pyrophosphatase 5.54/32.6 Q15181 122/8 Serum [33] Metabolism
44–47 Actin, cytoplasmic 2 5.31/41.7 P63261 79/6 Serum [28] Cell motility
48 Glutamine synthetase 6.43/44.7 P15104 13.94/1 Serum, Metabolism
Cerebrospinal
fluid [31]
49 Collagen alpha-1(III) chain 6.21/138.5 P02461 88/6 Extracellular Cell-cell
matrix [32]  interaction
50, 51 Retinol-binding protein 4 (RBP4) 5.76/23 P02753 109/9 Serum [28] Transport
52 Apolipoprotein A-I-binding 7.56/31.6 Q8NCW5 37/3 Serum, Transport,
 protein cerebrospinal metabolism
spinal fluid [29]
53 Transgelin-2 8.41/22.3 P37802 183/13 Serum [28] Cell mobility
54 Transketolase 7.58/67.8 P29401 213/16 Serum [30] Metabolism
aSwiss-Prot accession number; bSpots 1–22 were previously detected in lung cancer body fluids, 23–38 were detected in types of cancer other than
lung cancer body fluids, and the rest in other diseases’ body fluids
A B
Figure 1. Proteome of Mehr-80 (A) and QU-DB (B) large-cell lung cancer cell lines were separated using 2DE with
pH 3–10 nonlinear IPG strips and visualized by silver staining. The locations of the 54 spots in Table 1 are labeled
with numbers.  Spots 1–13, 21, 23–49 were observed in both QU-DB and Mehr-80 cell lines. Spots 14–16, 22 and
50–52 were invisible or hardly visible on Mehr-80 gels. Spots 17–20, 53 and 54 were invisible or hardly visible on
QU-DB gels
Membrane/membrane-bound proteins can be re-
leased into body fluids and serve as valuable serum
biomarkers, e.g. carcinoembryonic antigen in lung
cancer [1]. Some of the proteins we have identified
belong to this category. Examples of those which are
overexpressed in lung cancer and which deserve fur-
ther attention are annexin1 [14], T complex protein,
[38] and transketokase [40].
Most of the proteins identified in this study have
been reported to be present in media used to grow
human cancer cell lines [1–3, 11]. Several of them,
e.g. stathmin, are overexpressed in lung cancer. Stath-
min provokes microtubule depolymerisation and reg-
ulates microtubule-dependent processes including cell
division and motility. Its overexpression has been
linked to cell migration and invasion in lung adeno-
carcinoma and SCC [41]. Glutathione S-transferase
omega-1 [11], and chloride intracellular channel pro-
tein 4 (CLIC4) [11] have been found in lung cancer
cell line media compared to media derived from nor-
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mal lung tissue cell cultures, and the search for these
proteins in serum may be worthwhile.
It remains to be determined whether our candi-
date biomarkers are found in all types of lung cancer,
or are restricted to LCC. Because NSCLC studies
usually focus on SCC and adenocarcinoma, the cur-
rent data is insufficient to judge their specificity to
LCC. Among proteins identified in this study, lactate
dehydrogenase-B, a-enolase, IL-6, hsp-27, stress-in-
duced phosphoprotein 1, plasminogen activator in-
hibitor 1, vimentin, T-complex protein 1, and isoci-
trate dehydrogenase 1 were investigated in LCC [10,
38, 39, 42]. They were found to be significantly over-
expressed in adenocarcinoma and SCC subtypes in
addition to LCC. For vimentin and IL-6, there are
reports to show their increases in LCC compared to
other types of NSCLC [10, 39]. Vimentin, an inter-
mediate filament protein, usually expressed in mes-
enchymal cells, plays a role in cell movement. Vimen-
tin is a marker for epithelial to mesenchymal transi-
tion, a process that has been critically linked to can-
cer invasiveness [17]. Interestingly, the highest
percentage of vimentin positivity has been observed
in LCC compared to other subtypes of NSCLC (SCC
and adenocarcinoma) and SCLC [39].
In conclusion, we searched for potential biomark-
ers of lung cancer in conditioned media from two lung
cancer cell lines. Some of the identified proteins were
already suggested as being putative serum biomark-
ers for lung cancer, i.e. PGP9.5 and IL-6. Others, such
as IL-25, stathmin, vimentin, epidermal fatty acid-
binding protein, transgelin-2, stress-induced phos-
phoprotein 1 and CLIC4, should be further investi-
gated as possible biomarkers of LCC.
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